KeyNeurotek receive EMEA Orphan Drug Designation for KN38-7271 in TBI « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
September 2008

M T W T F S S

« Aug Oct »

1 2 3 4 5 6 7

8 9 10 11 12 13 14

15 16 17 18 19 20 21

22 23 24 25 26 27 28

29 30

KeyNeurotek receive EMEA Orphan Drug Designation for KN38-7271 in TBI

Posted on September 22, 2008 by crimsoncanary

KeyNeurotek Pharmaceuticals have received Orphan Drug Designation for its lead cannabinoid agonist compound KN38-7271 for the treatment of moderate and severe closed traumatic brain injury from EMEA

Filed under: Uncategorized | Tagged: Cannabinoid, Cannabinoid CB1, Cannabinoid CB2, CB1, CB2, regulatory

« AstraZeneca and Targacept present Phase IIb data on AZD3480 in Alzheimers Disease FDA Acute Chemotherapy-induced Nausea and Vomiting »

Leave a Reply